MHC class I+ and class I(-)HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in immunization/challenge experiments.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F03%3A23033177" target="_blank" >RIV/68378050:_____/03:23033177 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

MHC class I+ and class I(-)HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in immunization/challenge experiments.

Popis výsledku v původním jazyce

It has been demonstrated repeatedly that a high proportion of tumours derived from MHC class I+ precursors Are MHC class I-. Since a major task in immunotherapy strategies for treatment of malignancies is to develop polyvalent tumour vaccines efficient against a broad spectrum of tumours, we have examined whether MHC class 11 cell-based tumour vaccines can cross-protect against homologous MHC class I- tumour challenge and vice versa. For these purposes, we have used two oncogenic cell lines induced independently by co-transfection of murine H-2(b) cells with E6/E7 HPV16 and activated Ha-ras oncogenes, the tumours TC-1 (MHC class 11, HPV16 E7(+)) and MK16/1/IIIABC (MHC class I-, HPV16 E7(+)). Surprisingly, it was found that these two tumours do not cross-react, although both of them contain the crucial HPV16-coded tumour rejection antigen E7. Preimmunization with the MHC class I+ tumour did not protect against a subsequent challenge with the MHC class I- tumour and vice versa; however,

Název v anglickém jazyce

MHC class I+ and class I(-)HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in immunization/challenge experiments.

Popis výsledku anglicky

It has been demonstrated repeatedly that a high proportion of tumours derived from MHC class I+ precursors Are MHC class I-. Since a major task in immunotherapy strategies for treatment of malignancies is to develop polyvalent tumour vaccines efficient against a broad spectrum of tumours, we have examined whether MHC class 11 cell-based tumour vaccines can cross-protect against homologous MHC class I- tumour challenge and vice versa. For these purposes, we have used two oncogenic cell lines induced independently by co-transfection of murine H-2(b) cells with E6/E7 HPV16 and activated Ha-ras oncogenes, the tumours TC-1 (MHC class 11, HPV16 E7(+)) and MK16/1/IIIABC (MHC class I-, HPV16 E7(+)). Surprisingly, it was found that these two tumours do not cross-react, although both of them contain the crucial HPV16-coded tumour rejection antigen E7. Preimmunization with the MHC class I+ tumour did not protect against a subsequent challenge with the MHC class I- tumour and vice versa; however,

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2003

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Folia biologica

ISSN

0015-5500

e-ISSN

—

Svazek periodika

2003

Číslo periodika v rámci svazku

49

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

230-234

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—